SCIENTIFIC ADVISORY BOARD
Hamilton O. Smith, MD
Dr. Smith is chairman of the Scientific Advistory Board and the scientific director of the Institute of Biological Energy Alternatives. In 1978, Dr. Smith was a co-recipient of the Nobel Prize in Medicine for the discovery of Type II restriction enzymes, which led to the development of recombinant DNA technology. He has collaborated with The Institute for Genome Research (TIGR) to sequence the genome of H. influenza, archaea bacteria and other bacteria. He joined Celera in 1998 as director of DNA resources and participated in the sequencing of the genomes of the fruit fly, mosquito, mouse and human. Dr. Smith has received numerous awards and is a member of the National Academy of Sciences.
John Todd, FRS, FMedSci, FRCP Hons, PhD
Dr. Todd is Professor of Precision Medicine at the University of Oxford (until recently Professor of Medical Genetics at the University of Cambridge), Director of the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory (DIL) in the University’s Wellcome Trust Centre for Human Genetics, and a Senior Investigator of the National Institute for Health Research. He researches type 1 diabetes (T1D) genetics and disease mechanisms with an aim of clinical intervention, and his research has received several awards and prizes. In the latest phase of his research to translate basic genetic and immunological knowledge to treatment and prevention, the DIL has now completed its first two mechanistic, statistically adaptive, dose-finding trials in T1D patients. Dr. Todd and his team have established new and effective methods of trial design, governance, conduct and patient recruitment. This design and analyses have revealed several previously unknown effects of interleukin-2 (IL-2) on the human immune system, providing key information on the future possibility of using subcutaneous administration of ultra-low doses of IL-2 to preserve pancreatic islet beta-cell function to treat and prevent T1D. Dr. Todd has supervised 30 PhD students, with three in progress. He has an h-index of 94 and total citations over 36,000.
J. Craig Venter, PhD
Dr. Venter is presently the founder and president of The J. Craig Venter Science Foundation, The Center for the Advancement of Genomics and the Institute for Biological Energy Alternatives. Dr. Venter is well known for leading Celera to the successful sequencing of the human genome. Dr. Venter held numerous research positions at the National Institutes of Health, including chief of the receptor biochemistry and molecular biology section. He served as president and chairman of the board for The Institute for Genome Research. Dr. Venter is the recipient of numerous awards and honorary degrees, including the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize, the 2001 Takeda Award, the 2000 King Faisal Award and the 2002 Gairdner Foundation International Award. Dr. Venter is a member of the National Academy of Sciences.
BIOCHEMISTRY ADVISORY BOARD
Satish Kalhan, MD
Dr. Kalhan is a certified physician in both medicine and pediatrics whose research has focused on nutrition and metabolism. He has developed numerous isotopic tracer techniques for the study of whole body metabolism, and his major interests include whole body glucose, protein and amino acid metabolism in various physiological states such as pregnancy, infancy and adolescence. Dr. Kalhan has served on a number of advisory boards, consultative groups and peer review groups in these fields of research and clinical medicine.
Vern Schramm, PhD
Dr. Schramm is the Professor and Ruth Merns Chair of Biochemistry at the Albert Einstein College of Medicine in New York City. Dr. Schramm has received numerous honors in recognition of both his biochemistry research and teaching. He has been a member of the Einstein faculty since 1987 and is world-renowned for his research of transition state theory for enzyme-catalyzed reactions. Dr. Schramm's current research is focused on transition state analogues for treatment of leukemia, solid tumors, autoimmune diseases, bacterial infections, malaria and as antidotes for bioterrorism agents.
Steven Zeisel, MD, PhD
Dr. Zeisel is the Kenan distinguished university professor of nutrition at the University of North Carolina at Chapel Hill and serves as the director of the Nutrition Research Institute, a part of UNC's School of Public Health. Dr. Zeisel is recognized as an international leader in nutrition research. His team's work established the requirement for choline, a newly recognized essential part of our diet. His work on nutrition and brain development, genetic variation and diet requirements, environment and nutrition, and medical education are supported by grants from the U.S. National Institutes of Health (NIH). Dr. Zeisel directs one of the NIH national centers of excellence in human nutrition research.